VNDA Vanda: Multiplikator forward rega marang pendapatan

Logo perusahaan publik vandapharma.com (VNDA)

Vanda Pharmaceuticals (VNDA) adheres to standard environmental regulations regarding the disposal of laboratory waste. The issuer's forward P/S reflects the valuation dynamics of expected sales, while the 1.00 level captures recent values. The asset relies on robust R&D potential in CNS therapy, and the ownership of exclusive medications for schizophrenia and insomnia creates a protected market niche.

Vanda Pharmaceuticals Inc. - Multiplikator Forward P/S VNDA (periode 04.07.2022 - 13.11.2026)

Vanda - rincian analitis lan metrik utama (VNDA)

- rega pasar lan target rega analis:
Bagan rega Vanda Pharmaceuticals Inc.|VNDA - Rata-rata rega prakiraan
- data kapitalisasi saham perusahaan:
Biji pasar Vanda|VNDA - Nilai Total Perusahaan
- rincian valuasi buku bisnis:
Nilai Buku saben Saham Vanda Pharmaceuticals|VNDA - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku vandapharma.com|VNDA - Total Aset Bisnis
- rincian struktur utang lan likuiditas bisnis:
Total Utang marang Modal Vanda Pharmaceuticals|VNDA - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Vanda Pharmaceuticals|VNDA - Gunggung utang perusahaan|Utang marang nilai buku Vanda|VNDA - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Vanda Pharmaceuticals|Rasio cepet vandapharma.com
- rincian asil keuangan lan kelipatan valuasi:
VNDA - Bathi pungkasan|Proyeksi bathi mangsa ngarep Vanda Pharmaceuticals|VNDA - Pangali P/E|Rega marang bathi mangsa ngarep Vanda Pharmaceuticals Inc|VNDA - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Vanda|VNDA - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Vanda Pharmaceuticals|VNDA - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan vandapharma.com|VNDA - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Vanda Pharmaceuticals
- data total pendapatan lan volume dodolan:
VNDA - Total pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan Vanda Pharmaceuticals Inc.|VNDA - Multiplikator P/S|Multiplikator forward rega marang pendapatan Vanda
Analisis fundamental perusahaan:Vanda Pharmaceuticals Inc. (VNDA)
Sampel barang Vanda

Vanda Pharmaceuticals (VNDA) maintains a strong scientific reputation in the therapy of complex psychoneurological disorders, rendering its revenue dependent on the trust of the medical community. By analyzing the forward P/S ratio, an investor determines the cost of one dollar of expected sales to avoid overpaying for unfounded hopes and to accurately assess the asset's market balance relative to the company's future cash flows.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Alkermes ALKS|Avadel Pharmaceuticals PLC (AVDL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ATAI: Multiplikator forward rega marang pendapatan|GHRS: Rasio rega marang prakiraan pendapatan|MNMD: Multiplikator Forward P/S|compasspathways.com (CMPS) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan LB Pharmaceuticals|Kapitalisasi marang prakiraan pendapatan DRUG (Bright Minds Bio)|Multiplikator Forward P/S CYBN|Alto Neuroscience Corp - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S NRXP (NRx Pharmaceuticals)|Multiplikator Forward P/S Cingulate Inc CING|SILO: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CPHI (China Pharma Holdings)|Clearmind Medicine (CMND) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan PBM (Psyence Bio)|SPRC (SciSparc Ltd) - Multiplikator Forward P/S|SEEL: Rega forward marang dodolan|Multiplikator Forward P/S VRPX|Multiplikator Forward P/S Karuna Therapeutics Inc (KRTX)